Form 4: Gilead Sciences Director Sandra Horning Reports Stock Option Grant and RSU Vesting

Director Sandra Horning reports the acquisition of stock options and restricted stock units (RSUs) in Gilead Sciences, Inc.

Summary

• Sandra Horning, a director of Gilead Sciences, Inc., filed a Form 4 on May 8, 2025, reporting transactions related to the company's stock.
• On May 7, 2025, Horning was granted 1,516 restricted stock units (RSUs) under the 2022 Equity Incentive Plan, which vested immediately.
• Each RSU represents the right to receive one share of Gilead Sciences, Inc.'s common stock.
• Additionally, Horning was granted a non-qualified stock option to buy 6,809 shares of Gilead Sciences common stock at an exercise price of $98.90, which also vested immediately.
• Following these transactions, Horning beneficially owns 5,147 shares of common stock and 6,809 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices, aligning director interests with shareholders.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• Immediate vesting of the RSUs and stock options may incentivize the director to contribute to the company's success in the near term.

Industry Context

This filing is a routine disclosure of stock-based compensation to a company director, which is a common practice in publicly traded companies to incentivize and retain key personnel.

Stakeholder Impact

• The grant of equity to a director can align their interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates

Keywords

Gilead Sciences, Director, Sandra Horning, Form 4, RSU, Stock Option, Beneficial Ownership, Equity Incentive Plan